Arnulfo Mendoza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Arnulfo Mendoza has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Christine M. Heske
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
52 shared publications - Baktiar O. Karim
Frederick National Laboratory for Cancer Research
49 shared publications - Choh Yeung
Translational Sarcoma Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 1
49 shared publications - Ksenia Vulikh
Molecular Histopathology Lab, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 3
49 shared publications - Victor J. Collins
Translational Sarcoma Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 1
49 shared publications - Ariana E. Nelson
Translational Sarcoma Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 1
39 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
Combination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare, aggressive, chemoresistant malignancy with limited effective systemic therapies and few recurrent actionable oncogenic drivers. Although IGF-2 is overexpressed in approximately 80% of ACCs, clinical inhibition of the IGF-1R/InsR axis has not improved outcomes. To identify clinically tractable combination strategies that enhance IGF-1R/InsR inhibition in ACC, we performed a quantitative high-throughput combinatorial screen of 2,803 mechanistically annotated oncology compounds with the IGF 1R/InsR inhibitor linsitinib in an ACC cell line. Downstream effects of IGF-1R/InsR signaling were assessed to identify actionable nodes for combination targeting. Candidate combinations were validated using short-term ACC patient-derived organoids (PDOs) and patient-derived xenograft (PDX) models. The screen identified MAPK pathway inhibitors—particularly MEK inhibition—as the top synergistic partners with IGF-1R/InsR inhibition. Genetic or pharmacologic inhibition of IGF-1R/InsR and MEK signaling suppressed ACC growth in vitro. Downstream profiling of IGF-1R/InsR signaling identified AKT as a major effector, supporting direct AKT targeting as a translatable substitute for IGF-1R/InsR inhibition in ACC. Accordingly, the AKT inhibitor capivasertib synergized with the MEK inhibitor cobimetinib in ACC cell lines and six ACC PDO models. In vivo, combined AKT and MEK inhibition reduced tumor growth more than either agent alone in an ACC xenograft and two ACC chemotherapy-resistant PDX models with acceptable tolerability. These data identify AKT as a critical survival pathway in ACC and support combined AKT and MEK inhibition with FDA-approved agents as a therapeutic approach for chemotherapy-resistant ACC.
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
Open AccessCombination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare, aggressive, chemoresistant malignancy with limited effective systemic therapies and few recurrent actionable oncogenic drivers. Although IGF-2 is overexpressed in approximately 80% of ACCs, clinical inhibition of the IGF-1R/InsR axis has not improved outcomes. To identify clinically tractable combination strategies that enhance IGF-1R/InsR inhibition in ACC, we performed a quantitative high-throughput combinatorial screen of 2,803 mechanistically annotated oncology compounds with the IGF 1R/InsR inhibitor linsitinib in an ACC cell line. Downstream effects of IGF-1R/InsR signaling were assessed to identify actionable nodes for combination targeting. Candidate combinations were validated using short-term ACC patient-derived organoids (PDOs) and patient-derived xenograft (PDX) models. The screen identified MAPK pathway inhibitors—particularly MEK inhibition—as the top synergistic partners with IGF-1R/InsR inhibition. Genetic or pharmacologic inhibition of IGF-1R/InsR and MEK signaling suppressed ACC growth in vitro. Downstream profiling of IGF-1R/InsR signaling identified AKT as a major effector, supporting direct AKT targeting as a translatable substitute for IGF-1R/InsR inhibition in ACC. Accordingly, the AKT inhibitor capivasertib synergized with the MEK inhibitor cobimetinib in ACC cell lines and six ACC PDO models. In vivo, combined AKT and MEK inhibition reduced tumor growth more than either agent alone in an ACC xenograft and two ACC chemotherapy-resistant PDX models with acceptable tolerability. These data identify AKT as a critical survival pathway in ACC and support combined AKT and MEK inhibition with FDA-approved agents as a therapeutic approach for chemotherapy-resistant ACC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Assessment of cell confluency confirms DNA-PK inhibition selectively synergizes with etoposide
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Assessment of cell confluency confirms DNA-PK inhibition selectively synergizes with etoposide
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
The synergistic combination of the DNA-PK inhibitor M3814 and etoposide extends to multiple Ewing sarcoma cell lines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
The synergistic combination of the DNA-PK inhibitor M3814 and etoposide extends to multiple Ewing sarcoma cell lines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S7 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Etoposide combined with DNA-PK inhibition induces apoptosis in TP53 wild-type and mutant Ewing sarcoma cell lines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S7 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Etoposide combined with DNA-PK inhibition induces apoptosis in TP53 wild-type and mutant Ewing sarcoma cell lines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
A screen of multiple drug combinations demonstrates the selectivity of the synergistic activity of the DNA-PK clinical inhibitor M3814
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
A screen of multiple drug combinations demonstrates the selectivity of the synergistic activity of the DNA-PK clinical inhibitor M3814
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S9 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Evaluation of the DNA-PK inhibitors plus TOP2 poisons in preclinical models of EWS
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S9 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Evaluation of the DNA-PK inhibitors plus TOP2 poisons in preclinical models of EWS
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
The DNA-PKi enhancement of EWS cells sensitivity to etoposide DNA-PK inhibition is a class effect
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
The DNA-PKi enhancement of EWS cells sensitivity to etoposide DNA-PK inhibition is a class effect
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
TOP2 poisons synergize with DNA-PK inhibition in EWS
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
TOP2 poisons synergize with DNA-PK inhibition in EWS
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
In vivo compound preparation and administration information
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
In vivo compound preparation and administration information